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Electronic health record (EHR) data enhance opportunities for conducting surveillance of diabetes. The objective of 
this study was to identify the number of people with diabetes from a diabetes DataLink developed as part of the 
SUPREME-DM (SUrveillance, PREvention, and ManagEment of Diabetes Mellitus) project, a consortium of 11 
integrated health systems that use comprehensive EHR data for research.
Methods 
We identified all members of 11 health care systems who had any enrollment from January 2005 through December 
2009. For these members, we searched inpatient and outpatient diagnosis codes, laboratory test results, and 
pharmaceutical dispensings from January 2000 through December 2009 to create indicator variables that could 
potentially identify a person with diabetes. Using this information, we estimated the number of people with diabetes 
and among them, the number of incident cases, defined as indication of diabetes after at least 2 years of continuous 
health system enrollment.
Results 
The 11 health systems contributed 15,765,529 unique members, of whom 1,085,947 (6.9%) met 1 or more study criteria 
for diabetes. The nonstandardized proportion meeting study criteria for diabetes ranged from 4.2% to 12.4% across 
sites. Most members with diabetes (88%) met multiple criteria. Of the members with diabetes, 428,349 (39.4%) were 
incident cases.
Conclusion 
The SUPREME-DM DataLink is a unique resource that provides an opportunity to conduct comparative effectiveness 
research, epidemiologic surveillance including longitudinal analyses, and population-based care management studies 
of people with diabetes. It also provides a useful data source for pragmatic clinical trials of prevention or treatment 
interventions.
Introduction
For many years, diabetes registries have been used to assess and enhance clinical care provided by health systems (1). 
Initially, diabetes registries were created from administrative data such as inpatient diagnoses and pharmaceutical 
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dispensing data (2,3). Other early registries included insurance claims data that may have been incomplete because 
patients could receive care from multiple uncaptured sources (4). The more recent availability of detailed clinical data, 
including real-time laboratory test results, has improved the ability to build more sophisticated and accurate diabetes 
registries that capture more precisely defined cohorts of people with diabetes.
The Agency for Healthcare Research and Quality (AHRQ) recently published a user’s guide for creating and using 
patient registries (5). However, implementation of standardized methods for creating multisite diabetes registries and 
validating their accuracy is largely untried. Standardization of methods is especially important when data are 
aggregated and patterns of care are compared in diverse populations across multiple health systems (6). Many single-
site studies have validated administrative definitions of diabetes (4,7-11), but criteria for inclusion in registries often 
vary, rendering comparisons across systems difficult. Such differences are not trivial; Harris and colleagues showed 
that in a sample of residents of Ontario, Canada, diabetes prevalence ranged from 5% to 12%, depending on which 
combinations of laboratory, pharmacy, and diagnosis data were used to verify diabetes case status (12).
A standardized method for identifying people with diabetes from the detailed clinical information available in 
electronic health records (EHRs), applied across multiple health systems, would be a powerful tool for conducting 
comparative effectiveness research, monitoring trends, analyzing geographic variation, and conducting surveillance of 
prediabetes and diabetes. The objectives of this study were to identify people with diabetes from comprehensive EHR 
and administrative data of 11 integrated health systems and to estimate incident cases of diabetes among them.
Methods
Participating health systems
The SUrveillance, PREvention, and ManagEment of Diabetes Mellitus (SUPREME-DM) project is an AHRQ-funded 
study under the PROSPECT (Prospective Outcome Systems using Patient-specific Electronic data to Compare Tests) 
initiative that brings together a consortium of 33 diabetes researchers (Appendix) from 11 of the 18 member 
organizations of the HMO Research Network (HMORN). Health plans participating in SUPREME-DM include 6 
Kaiser Permanente regions (Northern California, Southern California, Northwest [Oregon/Washington], Hawaii, 
Colorado, and Georgia), as well as HealthPartners (Minnesota), Marshfield Clinic (Wisconsin), Geisinger Health 
System (Pennsylvania), Group Health Cooperative (Washington), and Henry Ford Health System (Michigan). These 11 
health plans had approximately 10 million enrollees in 2009.
Virtual data warehouse
During the past 10 years, the HMORN has developed a Virtual Data Warehouse (VDW) with initial support from the 
National Cancer Institute. The VDW is now an HMORN resource supported by member organizations and network 
consortia and has been described in detail elsewhere (13). Briefly, the VDW is a data model resulting from the efforts of 
8 working groups, each focused on a specific type of data (eg, laboratory results, pharmacy, enrollment), that map site-
specific data to a common standard. Each site maintains an operating and accessible version of the standardized data. 
Within each research center of the member systems, data extracted from confidential health plan databases are 
reconfigured into 14 core data tables using standard variable names and values. The data can be linked through a 
unique patient identifier common across tables. The VDW, from which the diabetes DataLink is constructed, enables 
use of standardized data extraction programs distributed to all participating sites. Each site constructs individual-level 
data sets for analysis and sends either aggregated or individual-level deidentified data sets to the lead site, where they 
are combined into overall comparable cohorts.
The VDW data are more comprehensive than the claims data available to commercial insurers, Medicare, or Medicaid 
because the VDW tables include extensive data from EHRs as well as administrative data. Nine of 11 SUPREME-DM 
participating systems use an EPIC-based EHR system (EPIC, Verona, Wisconsin). VDW tables include comprehensive 
laboratory results that are useful for establishing risk-factor levels (eg, glycosylated hemoglobin, fasting and random 
plasma glucose, serum lipids) and blood pressure, height, and weight measurements, all of which can be used to assess 
the presence and level of hyperglycemia, dyslipidemia, hypertension, and overweight/obesity. In all participating 
health plans, at least 90% of members have a pharmacy benefit that helps ensure near complete identification of drug 
dispensings.
Protection of human subjects
Each of the 11 participating health system–affiliated research organizations has its own institutional review board 
(IRB). Under a common review mechanism (14), the IRBs of 8 sites ceded review authority for construction of the 
DataLink to a ninth participating system (Kaiser Permanente Colorado), and 2 retained local IRB oversight. Because 
the DataLink currently consists of aggregate secondary observational data and holds only minimal risk of unauthorized 
disclosure of protected health information, we requested and received waivers of informed consent and Health 
Insurance Portability and Accountability Act (HIPAA) authorization. Nonetheless, we used several safeguards to 
minimize the possibility of breaches of confidentiality. Data sent to the lead site were aggregated so that reconstructing 
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observations on any single member in the analyses was impossible. These aggregated data were transferred to the lead 
site via a secure data transfer website that meets HIPAA and Medicare data security standards; every keystroke and all 
attached files were encrypted.
Future studies may require limited data sets for ancillary analyses, primary data collection, or implementation of 
interventions on samples of study participants drawn from the DataLink. Such studies will require separate IRB review 
and approval. Collaborating sites can always choose whether to participate in future studies and will decide whether to 
cede or retain review by their local IRB.
Identification of SUPREME-DM DataLink population
For the SUPREME-DM project, we identified all 15,765,529 members of the respective health systems, regardless of 
age, who had any enrollment (membership) from January 1, 2005 (the first year that all systems had complete EHR 
data), through December 31, 2009. The use of health plan members rather than all patients who received care in the 
delivery system allowed us to establish an unbiased denominator for calculation of population rates. Because we 
sought to capture all prevalent cases of diabetes and the earliest source of identification for incident cases, we searched 
for all available data from January 1, 2000 (the first year VDW data were available), through December 31, 2009, to 
create a series of dichotomous indicator variables that could be used to identify possible diabetes, while retaining the 
dates and values of the qualifying indicators. These included inpatient or outpatient diagnoses of diabetes, laboratory 
test results conducted in an outpatient setting that were diagnostic of diabetes, and pharmaceutical dispensings.
Identification of members with diabetes
Using the indicator variables, we applied an algorithm to estimate the number of members with diabetes (Table 1). For 
criteria comprising 2 elevated laboratory values from the same test, we required the tests be performed on separate 
days but no more than 2 years apart. Two outpatient diagnoses were also required to occur on separate days. We 
excluded members with only a metformin, exenatide, or thiazolidinedione dispensing who met no other criteria to 
ensure that women with polycystic ovary syndrome or members with prediabetes were not included. To avoid 
including women with gestational diabetes, indicators were not considered during periods of pregnancy, defined as 
delivery date minus 270 days. The resulting data set is a dynamic cohort that can be linked to all available VDW data, 
thus allowing for longitudinal analyses of people with diabetes. Because many people join their health system after 
diabetes has been diagnosed, the first recognition of diabetes cannot be assumed to be the first date of diagnosis, and 
the source of diabetes identification for these people has little meaning. For this report, we calculated years of 
enrollment with diabetes from the first date associated with an indication of diabetes until December 31, 2009, or the 
last date of health system eligibility, whichever came first.
Identification of incident diabetes
We considered a member to have incident diabetes if the first indication of diabetes followed at least 2 years of 
continuous enrollment in a health system with no other indication of diabetes. For these members, we considered the 
date associated with the first indication of diabetes to be equivalent to a diagnosis date, and years of enrollment with 
diabetes to be equivalent to diabetes duration, calculated as time between diagnosis date and end of health system 
membership or December 31, 2009, whichever came first. Because our earliest EHR information was from 2000, by 
definition, our earliest incident cases were identified in 2002. Thus, although we can identify incident cases, we cannot 
estimate a true diabetes incidence rate from these data because requiring 2 years of eligibility before diabetes 
identification creates a subset of members with different inclusion criteria than the total population, and thus different 
denominators.
Results
Size of the population with diabetes
The 11 systems contributed 15,765,529 unique members over the 5-year period, of whom 1,085,947 (6.9%) met the 
SUPREME-DM DataLink criteria for diabetes (Table 2). On average, these members had 5 years of health system 
membership following diabetes identification. Mean age at diabetes identification (55.7 y) and the proportion who 
were women (48.1%) were consistent across systems.
Of the members identified as having diabetes, 39.4% (n = 428,349) were incident cases, for whom we were able to 
estimate a date of diagnosis and who had a mean of 3.3 years of membership following diagnosis (Table 3). Overall, 
9.9% of incident cases were first identified from inpatient diagnoses, 22.6% from outpatient diagnoses, 20.7% from 
pharmaceutical dispensings, and 46.8% from outpatient laboratory test results. There was considerable variability 
between systems in how incident cases were recognized. For example, the proportion first identified by laboratory tests 
ranged from 17.8% to 67.3%.
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Discussion
The SUPREME-DM project has united a large consortium of researchers with extensive expertise in childhood, adult, 
and gestational diabetes to identify more than 1 million unique individuals with diabetes from comprehensive EHR 
and administrative data of 11 integrated health systems, of whom 428,349 had incident diabetes. Because the DataLink 
is constructed from comprehensive inpatient, outpatient, pharmaceutical dispensing, and laboratory results data 
available from the EHR, clinical, and administrative databases of each of these health care systems, and because these 
data are extracted from defined populations with a known denominator, the DataLink is a unique resource for 
conducting comparative effectiveness research, surveillance, and epidemiologic studies of unprecedented scale and 
clinical detail.
Use of registries has enhanced medical care for patients with diabetes in individual health care systems for 2 decades 
(1). Indeed, several of the participating sites were early developers of diabetes registries derived from electronic data 
(2,3,11,15,16) and have used these registries for clinical care, quality improvement, and research purposes. However, 
these registries have traditionally been limited to patients served by only 1 health care delivery system, and variation in 
how registries were created has impeded cross-system comparisons (9). One major goal of the SUPREME-DM 
DataLink is to standardize data definitions across participating systems to provide the best possible estimates of 
diabetes and its complications. The variability among organizations in the proportion of people with diabetes and the 
source of recognition of incident cases emphasizes the need for this next step.
Although useful for more limited analyses, other previous or existing electronic registries cannot provide equivalent 
data for analysis. For example, in conjunction with the Centers for Disease Control and Prevention, a collaboration of 3 
managed care organizations developed a unified system in 1998 for conducting diabetes surveillance, tracking health 
services, and delivering preventive care (17). That system has not been maintained. The Department of Veterans 
Affairs (VA) has an excellent linked national database of VA patients that has been used to identify patients with 
diabetes, but the population is not representative because patients are predominantly male and sicker than the overall 
population of patients with diabetes (8). One diabetes database recently developed by the University of Pittsburgh 
Medical Center (UPMC) represents a more heterogeneous population, combining data from a large number of insurers 
(18) but covering only a single region. It is unclear whether the UPMC database will be routinely refreshed or whether 
a denominator of patients with and without diabetes can be easily identified, an essential component for estimating 
rates of diabetes and its complications. After assessment of other US diabetes databases, we believe the SUPREME-
DM DataLink is unique in its size, comprehensiveness, and geographic coverage.
Currently, the best estimates of US adult diabetes prevalence emerge from analyses of the National Health and 
Nutrition Examination Survey (NHANES). Those data suggest that 7.7% of the US adult population (aged ≥20 y) had 
diabetes in 2005–2006 (19). Similarly, we found that 6.9% of all enrollees (including children) in the SUPREME-DM 
DataLink have diabetes. NHANES identifies people with diabetes on the basis of self-report and by a single, 
unconfirmed elevated laboratory test result. Our DataLink has much more robust parameters to confirm diabetes 
status. Furthermore, as a cross-sectional survey, NHANES can estimate diabetes prevalence but not diabetes 
incidence. The longitudinal nature of the DataLink will allow the estimation of the incidence of diabetes and its 
complications, a unique feature that holds promise for future research and national surveillance efforts.
As recently noted by the Institute of Medicine (IOM), no surveillance system operates nationally and in a coordinated 
manner to integrate current and emerging data (20). The IOM report calls for a system that includes data on incidence 
and prevalence over time, primary and secondary prevention (including early detection), health outcomes following 
surveillance, representative samples, and disparities, noting that EHR data will play a key role in the surveillance of 
chronic disease. The SUPREME-DM DataLink answers that call by using the actual medical records of more than 15 
million people. The comprehensive EHR data available to the DataLink can be used to conduct population-based 
studies of the complications of diabetes while accounting for a wide range of demographic and clinical characteristics 
that independently contribute to risk. Furthermore, by examining data before and after diabetes diagnosis, the 
SUPREME-DM DataLink can be used to study the complete natural history of hyperglycemia and its associated 
complications.
Despite our standardized definition of diabetes, we observed variation across sites in how members with incident 
diabetes were initially identified. In addition to differences in the demographic makeup of the site-specific populations, 
there are several possible explanations. Although each of the 11 sites participating in SUPREME-DM is an integrated 
health care delivery system, their organizational structures differ (even across the 6 Kaiser Permanente regions). 
Furthermore, laboratory tests may not use the same reference ranges in all sites, and the use of hemoglobin A1c 
(HbA1c) assays, although moving toward standardization, could introduce variation. Differences in how providers code 
diagnoses during outpatient encounters or the inclusion of diagnostic codes linked to laboratory procedures or 
prescriptions could also introduce variation in the identification of diabetes across sites. Incomplete data capture at 
some sites, specifically of laboratory tests conducted outside the system or prescriptions filled outside of system 
pharmacies, could also contribute to variation. Site differences in ascertainment may lead to apparent but artificial 
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differences in diabetes duration or severity — a topic for future SUPREME-DM research. These possibilities are all 
under investigation. Despite these potential sources of variation in diabetes identification across sites, however, it is 
likely that a patient with diabetes in any of the systems will be recognized in a reasonably short period of time, 
especially when multiple data sources such as pharmacy, diagnosis codes, and laboratory results are used for this 
purpose. Indeed, approximately 85% of diabetes cases in all sites had multiple indications.
As with any observational data collected for health care and payment, there are potential limitations to the SUPREME-
DM DataLink. Inconsistencies in data availability (eg, not all sites can distinguish between random and fasting glucose 
tests) may preclude use of the DataLink for certain purposes or require exclusion of some participating centers from 
specific analyses. Unrecognized or unmeasurable differences among our study sites in the use of EHRs and the 
completeness of data could lead to inaccuracies and potential bias in the estimation of diabetes incidence and 
prevalence. The patient populations in integrated health delivery systems may not generalize to patients managed in 
less integrated settings, in other geographic areas, or to uninsured populations. A common case identification 
algorithm was used to identify members with diabetes across all SUPREME-DM sites, but we did not have the 
resources to individually validate each case through medical record review. Thus, ancillary studies should use caution 
when approaching individual health plan members because of the occasional member with a coded diagnosis who may 
not truly have diabetes. An additional limitation is the inability to distinguish members with type 1 and type 2 diabetes 
with a high level of precision. Finally, date of diabetes diagnosis, an important element in analyses of the natural 
history and clinical outcomes of diabetes, is not known for 60% of the diabetes cases.
We are expanding the DataLink to include members at risk for developing diabetes on the basis of elevated fasting 
glucose, glucose tolerance, or HbA1c tests that do not meet diagnostic criteria for diabetes, and to identify women with 
gestational diabetes. Data for additional years (2010–2012) will be added as they become available. The SUPREME-
DM DataLink is a valuable resource that provides an opportunity to conduct comparative effectiveness research, 
epidemiologic surveillance including longitudinal analyses, and population-based care management studies of people 
with diabetes, gestational diabetes, and prediabetes, and to explore associated risk factors, complications, and health 
outcomes in new ways. The DataLink also provides an excellent source for pragmatic clinical trials of preventive or 
treatment interventions to improve the health and quality of care for people with diabetes.
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Table 1. SUPREME-DM DataLink Project Criteria for Identifying Members 
With Diabetes
Criterion Value Details
Dispense of sulfonylurea, insulin, biguanide, 
thiazolidinedione, α-glucosidase inhibitor, 
incretin mimetic, meglitinide, amylin analog, or 
dipeptidyl peptidase inhibitor
≥1 Dispense Not valid if dispense was for metformin, any 
thiazolidinedione, or exenatide AND none of the 
other criteria were met
OR
HbA1c ≥2 at ≥6.5% Tests must be on separate days no more than 2 
years apart.
OR
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Criterion Value Details
Fasting plasma glucose ≥2 at ≥126 
mg/dL
Tests must be on separate days no more than 2 
years apart.
OR
Random plasma glucose ≥2 at ≥200 
mg/dL
Tests must be on separate days no more than 2 
years apart.
OR
Random plasma plus fasting glucose 1 at ≥200 
mg/dL AND 1 
at ≥126 mg/dL
Tests must be on separate days no more than 2 
years apart.
OR
HbA1c plus fasting glucose 1 at ≥6.5% 
AND 1 at ≥126 
mg/dL
Tests can occur on same day but cannot be more 
than 2 years apart.
OR
HbA1c plus random plasma glucose 1 at ≥6.5% 
AND 1 at ≥200 
mg/dL
Tests can occur on same day but cannot be more 
than 2 years apart.
OR
2-h 75-g OGTT 1 at ≥200 
mg/dL
Do NOT count if measured during pregnancy.
OR





Outpatient visit diagnosis ≥2 (250.x, 
357.2, 366.41, 
362.01–362.07)
Visits must occur on separate days. Ambulatory 
visits only. Do not include telephone, e-mail, 
emergency department, laboratory, radiology, or 
other encounter types.
Abbreviations: HbA1c, hemoglobin A1c; OGTT, oral glucose tolerance test.
 
Table 2. Total Health Plan Enrollment and Number of Members With 






Mean Years of Enrollment 
After Diabetes Diagnosis




1 836,169 51,989 (6.2) 5.1 56.6 48.7
2 4,904,140 361,894 (7.4) 5.4 56.5 48.0
3 305,968 20,331 (6.6) 5.3 59.4 52.0
4 5,488,817 389,647 (7.1) 5.0 55.8 47.0
5 568,157 31,842 (5.6) 4.3 52.9 49.2
6 224,821 27,781 (12.4) 5.6 58.1 52.5
7 220,934 26,680 (12.1) 4.6 60.7 49.7
8 1,463,011 61,212 (4.2) 4.8 54.6 47.1
9 392,858 30,066 (7.7) 5.4 56.8 52.2
a






Mean Years of Enrollment 
After Diabetes Diagnosis




10 577,495 42,926 (7.4) 5.1 57.1 51.0
11 783,159 41,579 (5.3) 5.0 57.7 47.6
Total 15,765,529 1,085,947 (6.9) 5.0 55.7 48.1
 Calculated as number of years following first indication of diabetes as described in Table 1 until end of health system 
enrollment or December 31, 2009, whichever came first.
 
Table 3. Number of Incident Diabetes Cases, Years of Membership 






Mean Years of 
Enrollment With 
Diabetes










1 18,287 3.3 11.0 17.5 16.6 54.9
2 151,177 3.6 9.6 20.0 20.1 50.2
3 7,248 3.3 14.4 36.2 12.4 37.0
4 153,473 3.4 9.8 18.9 23.2 48.1
5 10,149 3.2 15.0 26.7 26.8 31.5
6 12,062 3.5 6.1 41.4 17.0 35.5
7 8,253 2.7 16.6 40.5 11.9 31.0
8 27,096 3.1 4.3 51.2 26.7 17.8
9 11,832 3.5 8.5 13.7 10.5 67.3
10 15,059 3.3 14.2 19.0 16.3 50.5
11 13,713 3.4 12.7 16.9 16.0 54.5
Total 428,349 3.3 9.9 22.6 20.7 46.8
 Number of diabetes cases with at least 2 years of health system eligibility before first indication of diabetes. 
 Calculated as number of years following first indication of diabetes until end of health system enrollment or December 31, 
2009, whichever came first. 
 Based on study criteria in Table 1, the source of the earliest indication of diabetes.
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